Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

ENDO 2025 Tirzepatide Outperforms Semaglutide on Combined T2D Goals Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.